NEW YORK (GenomeWeb News) – CytRx subsidiary RXi Pharmaceuticals has licensed RNAi sequences from Thermo Fisher Scientific to a number of target genes for use in the development of therapeutic compounds for several common diseases, RXi said today.
Under the agreement, RXi will use RNAi sequences generated by Thermo Fisher Dharmacon’s sequence selection algorithm for its rxRNA compound program, which focuses on developing therapeutics for type 2 diabetes, obesity, neurology, and oncology.
RXi said the agreement covers around 100 RNAi sequences per target gene.
Financial terms of the agreement were not disclosed.